Charles River and Deciphex Expand Partnership to Enhance Digital Pathology with Exclusive Image Management Solutions
Charles River Laboratories (NYSE: CRL) and Deciphex, a leader in AI-powered digital pathology, have announced the next phase of their strategic collaboration. The focus will be on advancing state-of-the-art image management solutions and developing innovative AI tools for toxicologic pathology. This partnership aims to provide a fully integrated workflow for image management, distribution, and archiving, ensuring enhanced efficiency, precision, and scalability in pathology operations.
Charles River Laboratories and Deciphex have announced an exciting next phase in their partnership, advancing digital workflows for non-clinical safety assessments. The collaboration focuses on transforming how pathology data is managed and analyzed by integrating Deciphex’s Patholytix platform into Charles River’s global operations. This move is set to enhance efficiency, collaboration, and accuracy, accelerating drug development and ensuring safer therapies reach patients more quickly.
Professor Julie Frearson, PhD, Corporate Senior Vice President and Chief Scientific Officer at Charles River, shared her enthusiasm about the partnership: “Patholytix has transformed how we manage and analyze pathology data, enabling unprecedented efficiency and collaboration across our global teams. This next phase of our partnership with Deciphex marks a significant milestone in advancing digital workflows for non-clinical safety assessments.”
Transforming Image Management for Pathology
At the core of the partnership is the integration of Patholytix into Charles River’s operations. This innovative solution allows histology laboratories and pathologists throughout the Charles River network to manage, share, and archive toxicologic pathology data with unmatched capabilities. The integrated system will streamline digital workflows, reduce turnaround times, and foster seamless collaboration across teams worldwide. By simplifying the management of complex pathology data, this partnership aims to accelerate the pace of drug discovery while improving safety assessments.
Donal O’Shea, CEO of Deciphex, emphasized the transformative nature of the collaboration: “The exclusive integration of Patholytix into Charles River’s operations represents a transformative step in our mission to revolutionize digital pathology. This partnership exemplifies our commitment to delivering innovative solutions that enhance efficiency, drive collaboration, and ultimately accelerate safer drug discovery.”
Advancing AI Applications in Toxicologic Pathology
One of the key goals of the collaboration is to enhance AI-powered solutions for toxicologic pathology. Building on the success of the 2024 launch of the Foresight platform, the partnership will extend AI applications in new areas, such as screening tools for acute toxicity and carcinogenicity studies. These AI advancements will broaden tissue and lesion coverage, allowing for more comprehensive and accurate assessments in toxicology.
The focus is to further improve non-clinical toxicology studies by leveraging AI to reduce the time and resources required for these evaluations. This, in turn, will allow pathologists to focus on high-value diagnostic tasks and accelerate drug development timelines. By incorporating AI technology into the workflow, the partnership is driving innovation in toxicologic pathology and ensuring that drug candidates undergo thorough safety evaluations before moving forward in the development process.
Efficiency Gains for Pathology Workflows
The combination of digital pathology solutions and AI-powered tools is expected to deliver significant efficiency gains. The integrated system will streamline pathology workflows and reduce the time needed for non-clinical toxicology studies. Pathologists will be able to focus on more complex and high-value diagnostic activities, improving the accuracy of their assessments and the overall quality of the drug discovery process.
By combining Deciphex’s advanced digital pathology solutions with Charles River’s established toxicologic pathology network, clients of both organizations will benefit from a comprehensive, technology-driven system that accelerates primary evaluation and peer review. This will ultimately enhance decision-making in drug discovery and safety assessments, ensuring that drugs are rigorously tested and safe for use before they reach the market.
About Charles River
Charles River is a global leader in providing essential products and services that help pharmaceutical and biotechnology companies, government agencies, and academic institutions accelerate their research and drug development efforts. The company is dedicated to improving and expediting the discovery, early-stage development, and safe manufacture of new therapies, with a focus on delivering the best possible outcomes for patients.
About Deciphex
Deciphex is a pioneering company at the forefront of digital pathology transformation. Leveraging AI-driven solutions and collaborating with global pathologists, Deciphex enhances pathology reporting accuracy, ultimately advancing drug development and improving patient care. With platforms like Diagnexia and Patholytix, Deciphex is redefining the future of pathology through innovation and cutting-edge technology.
